SoFi CEO enters prepaid forward contract on 1.5 million shares
LONDON - EKF Diagnostics Holdings plc (AIM: EKF), a global diagnostics company, has completed the buyback of 278,000 of its own ordinary shares, the company announced on Monday. The shares were acquired at a uniform price of 22.5 pence per share and will be held in treasury.
The transaction occurred on April 4, 2025, and was executed on the AIMX trading venue, with two separate trades comprising 196,020 shares at 11:59:28 and 81,980 shares at 16:21:13. Following the buyback, EKF's total issued share capital stands at 454,930,564 ordinary shares, each with one voting right. However, 2,319,693 of these shares are now held in treasury, reducing the total number of voting rights to 452,610,871.
As part of the buyback, EKF acquired 81,980 ordinary shares from Harwood, which manages investments for Oryx. This transaction was facilitated to maintain the aggregate indirect beneficial interest of Mr. Christopher Mills, a Non-Executive Director of EKF, at a level that does not exceed 30% of the company's total voting rights. Post-transaction, Mr. Mills' interest in EKF is 133,470,367 ordinary shares.
The share buyback comes as part of EKF's strategy to manage its capital structure and return value to shareholders. The company, which specializes in point-of-care analyzers in hematology and diabetes, as well as life sciences services, operates manufacturing sites in the United States and Germany and sells products in over 120 countries.
This announcement contains inside information as defined under Article 7 of EU Regulation 596/2014 and has been arranged for release by Julian Baines, the Executive Chair of EKF. The company's market performance and strategic decisions, such as this share buyback, are closely watched by investors for indications of financial health and management confidence.
The information in this article is based on a press release statement from EKF Diagnostics Holdings plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.